Skip To Main Content
Barbara B. Bendlin on Muck Rack

Barbara B. Bendlin

As seen in: Nature, Wiley Online Library, MDPI, JAMA (The Journal of the American Medical Association), JAMA Network, The Lancet, Neurology, European Respiratory Journal, The Journal of Allergy & Clinical Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara B.

Contact Barbara B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology

|
By Vaibhav Vemuganti, Qijun Zhang, Eric McGregor, James R. Hilser, Rubén Aquino-Martínez, Sandra Harding, Katharina Beck, Hailey Bussan, Yuetiva Deming, Rachel Studer, Sterling Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Corinne D. Engelman, Hooman Allayee, Rozalyn Anderson, Tyler K. Ulland, Fredrik Bäckhed, Barbara B. Bendlin, Federico E. Rey, Joseph Lawrence Harpt, Jessamine F. Kuehn
| Nature Verified
Abstract The gut microbiome modulates metabolic and neurovascular processes implicated in Alzheimer’s disease and related dementias (ADRD), but the underlying mechanisms remain unclear. Here, we identify the bacterial metabolite imidazole propionate (ImP) as a modifier of ADRD pathology. In a cohort of 1196 cognitively unimpaired adults, higher plasma ImP levels were associated with lower preclinical cognitive scores and biomarkers of ADRD, both cross-sectionally and longitudinally.
Open in Who Shared Issue with article?

Melatonin: A potential nighttime guardian against Alzheimer’s - Molecular Psychiatry

|
By Zefan Zhang, Barbara B. Bendlin, Henrik Zetterberg, Fernanda De Felice
| Nature Verified
Abstract In the context of the escalating global health challenge posed by Alzheimer’s disease (AD), this comprehensive review considers the potential of melatonin in both preventive and therapeutic capacities. As a naturally occurring hormone and robust antioxidant, accumulating evidence suggests melatonin is a compelling candidate to consider in the context of AD-related pathologies.
Open in Who Shared Issue with article?

The iterative process of fluid biomarker development and validation in Alzheimer's disease

|
By Barbara B. Bendlin, Henrik Zetterberg
| Wiley Online Library Verified
PDF ShareShare Alzheimer's disease (AD) is a progressive neurodegenerative dementia for which disease-modifying treatments, likely to be the most effective in early disease stages, are now being developed at a rapid pace.1 AD-related pathologies, key among which are extracellular amyloid beta (Aβ) plaques, intra-neuronal tau tangles, and neurodegeneration, as well as astrocytic and microglial activation, are evident in the brain decades before symptom onset; it is increasingly recognized that...
Open in Who Shared Issue with article?
See all 11 licensed articles (12 Total)